XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Operating Segment (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
Number of operating segments | segment     1  
Total research and development expenses $ 2,050,585 $ 587,503 $ 4,424,724 $ 1,472,801
Single reportable segment        
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES        
External clinical development expenses 1,637,683 206,277 3,334,914 763,237
Personnel related and stock-based compensation 258,072 260,349 687,490 472,619
Other research and development expenses 154,830 120,877 402,320 236,945
Total research and development expenses $ 2,050,585 $ 587,503 $ 4,424,724 $ 1,472,801